Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex

Fig. 2

Sur-X exerted specific anticancer effect in colorectal cancer cells in vitro. a-b Cell viability was determined by MTT assay in human colorectal cancer cells HCT116 and RKO treated with indicated concentrations of Sur-X or Con for 1 h, 3 h, 6 h or 24 h. Mean and SD of three independent experiments are shown. c Cell viability was determined by MTT assay in human peritoneal mesothelial cell line SV5. Mean and SD of three independent experiments are shown. d Representative images of colonies formation in HCT116 and RKO cells with or without treatment of 10 μM Sur-X or Con (top). The number of colonies was presented as percentage of no-treatment group, mean and SD of three independent experiments are shown (bottom). NT, no treatment. e The expression of survivin and XIAP in RKO, HT29, HCT116, HCT15 and SV5 was detected by Western blot analysis. GAPDH was used as a loading control. Three independent experiments were performed. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant

Back to article page